|
AU2016208280A1
|
|
Furin-knockdown and gm-csf-augmented (fang) cancer vaccine
|
|
AU2015252009A1
|
|
Furin-knockdown and gm-csf-augmented (fang) cancer vaccine
|
|
US2015086619A1
|
|
Individualized cancer therapy
|
|
US2014242639A1
|
|
Construction of bifunctional short hairpin RNA
|
|
US2014093888A1
|
|
Highly pure plasmid dna preparations
|
|
US2014134236A1
|
|
Individualized cancer therapy
|
|
WO2013170071A1
|
|
Bi-functional short-hairpin rna (bi-shrna) specific for single-nucleotide kras mutations
|
|
WO2013151981A1
|
|
Ewing's sarcoma bifunctional shrna design
|
|
US2013259926A1
|
|
BI-FUNCTIONAL shRNA TARGETING MESOTHELIN AND USES THEREOF
|
|
US2013259925A1
|
|
METHODS AND COMPOSITIONS TO TREAT CANCER USING BIFUNCTIONAL SRC 3 shRNA
|
|
AU2013201841A1
|
|
Furin-knockdown and gm-csf-augmented (fang) cancer vaccine
|
|
AU2013200827A1
|
|
Targeted delivery using tissue-specific peptidomimetic ligands
|
|
WO2013106592A1
|
|
Antagonists of mir-196a
|
|
WO2013036879A1
|
|
Compositions and methods for treating prostate cancer
|
|
SG188160A1
|
|
Furin-knockdown and gm-csf-augmented (fang) cancer vaccine
|
|
WO2011079070A1
|
|
Furin-knockdown bi-functional rna
|
|
CN102782139A
|
|
Novel therapeutic RNA interference technology targeted to the PDX-1 oncogene in PDX-1 expressing neuroendocrine tumors
|
|
US2011081403A1
|
|
Histone octamers for increased nucleic acid transfer
|
|
KR20120063503A
|
|
Targeted delivery using tissue-specific peptidomimetic ligands
|
|
SG2014015010A
|
|
Highly pure plasmid dna preparations and processes for preparing the same
|
